TLSA Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (21 mai 2024 @ 19:27):

Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology...

Stats
Dagens volum	101 578
Gjennomsnittsvolum	198 846
Markedsverdi	83.00M
EPS	$0 ( 2024-04-22 )
Neste inntjeningsdato	( $0 ) 2024-05-27
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-4.74
ATR14	$0.00800 (1.01%)

Volum Korrelasjon

Lang: 0.15 (neutral)

Kort: -0.88 (strong negative)

Signal:(43.264) Neutral

Tiziana Life Sciences PLC Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner
FITBP	-0.876
ACGLN	-0.87
PFF	-0.853
ENLV	-0.842
RCEL	-0.838
JSM	-0.837
ADSK	-0.827
FITBO	-0.814
FTXH	-0.811
BJK	-0.806

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Tiziana Life Sciences PLC Korrelasjon - Valuta/Råvare

0.20
( neutral )

0.40
( neutral )

0.00
( neutral )

0.64
( weak )

0.00
( neutral )

-0.62
( weak negative )

Tiziana Life Sciences PLC Økonomi

Annual	2022
Omsetning:	$0
Bruttogevinst:	$-51 000.00 (0.00 %)
EPS:	$-0.160

FY	2022
Omsetning:	$0
Bruttogevinst:	$-51 000.00 (0.00 %)
EPS:	$-0.160

FY	2021
Omsetning:	$0.00
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-0.139

FY	2020
Omsetning:	$0.00
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-0.120

Financial Reports:

No articles found.

Tiziana Life Sciences PLC Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Tiziana Life Sciences PLC

Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti-Interleukin 6 receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients. The company was incorporated in 1998 and is headquatered in London, the United Kingdom.